Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 FIGO stage of ovarian cancer, according to the presence or absence of venous thromboembolism.

From: Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study

Extent of stage Ovarian cancer without VTE Ovarian cancer less than 4 months after VTE Ovarian cancer 4 months to 27 years after VTE
  (n = 12,707) (n = 50) (n = 78)
    Prevalence Ratio (95% CI)a   Prevalence Ratio (95% CI)a
Patients with data on stage 11,946 (94%) 47 (94%)   68 (87%)  
Stage I 1,432 (12%) 3 (6%)   9 (13%)  
Stage II 1,600 (13%) 8 (17%)   7 (10%)  
Stage III 5,229 (44%) 20 (43%)   28 (41%)  
Stage IV 3,685 (31%) 16 (34%) 1.1 (0.8–1.5) 24 (35%) 1.1 (0.8–1.5)
  1. Because of rounding, not all column percentages total 100%. Percentages for patients with data on stage are of the entire group of patients. Percentages for patients in the stage categories are of patients with data.
  2. aThe prevalence ratio is the prevalence of patients with stage IV and VTE divided by the prevalence of patients with stage IV and no VTE, adjusted for age.